OvuGel by is a Animal medication manufactured, distributed, or labeled by Aurora Pharmaceutical, Inc.. Drug facts, warnings, and ingredients follow.
WITHDRAWAL PERIOD:
No withdrawal period is required when used according to labeling.
USER SAFETY WARNINGS:
Not for Use in Humans. Keep Out of Reach of Children. The Material Safety Data Sheet (MSDS) contains more detailed occupational safety information.
ANIMAL SAFETY WARNINGS:
OvuGel® should not be used in sows with obvious reproductive tract abnormalities.
OvuGel® should be administered intravaginally at approximately 96 hours after weaning. The product should be warmed at room temperature for a minimum of 10 minutes prior to use. Insert the delivery tube into the vagina so that the tip rests 1/2 inch (1-3 cm) posterior to the cervix. Use a separate sheath over the delivery tube for each sow treated. Each sow should receive a single 2 mL dose of OvuGel®. Sows should be inseminated 22 +/- 2 hours following administration of OvuGel® using standard artificial insemination techniques. Sows should be exposed to a boar during time of insemination. (See end of package insert for more detailed directions for OvuGel® administration).
Store at refrigerator temperature 36-46°F (2-8°C). Excursions permitted to 77°F (25°C) for no more than 5 days during shipping.
OvuGel® should be administered within 1 hour of warming; unused portions may be refrigerated immediately after use. The bottle stopper may be punctured a maximum of three times. Discard 28 days after the stopper is first punctured.
To obtain an MSDS, for technical assistance, or to report adverse events, contact Aurora Pharmaceutical at 1-888-215-1256 or www.aurorapharmaceutical.com. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS, or www.fda.gov/reportanimalae.
Principal Display Panel – 52.5 mL Bottle Carton
OvuGel®
(triptorelin acetate)
100 mcg triptorelin per mL (as triptorelin acetate)
Gel for intravaginal use
INDICATIONS FOR USE:
For the synchronization of time of insemination in weaned sows to facilitate a single fixed-time artificial insemination.
Not approved for use in gilts. Safety and effectiveness have not been evaluated in these animals.
Net Contents: 52.5 mL
multi-dose bottle (26 doses, 2 mL each)
Approved by FDA under NADA # 141-339
NDC: 51072-087-00
Manufactured by: Aurora Pharmaceutical, Inc.
1196 Hwy 3 S
Northfield, MN 55057
IN 40-1859 Rev. 02/2025
Reorder No: 59030

| OVUGEL
triptorelin acetate gel |
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
| Labeler - Aurora Pharmaceutical, Inc. (832848639) |
| Establishment | |||
| Name | Address | ID/FEI | Business Operations |
|---|---|---|---|
| Aurora Pharmaceutical, Inc. | 832848639 | manufacture | |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() OVUGEL 78175599 not registered Dead/Abandoned |
EiEiCo, Inc. 2002-10-17 |
![]() OVUGEL 77674437 not registered Dead/Abandoned |
L. Perrigo Company 2009-02-20 |
![]() OVUGEL 77275688 3835525 Live/Registered |
UNITED ANIMAL HEALTH, INC. 2007-09-10 |